The Genome Editing Market is expected to grow significantly due to advancements in gene therapy technologies and the increasing demand for genetically modified organisms (GMOs) in agriculture and ...
BofA downgraded Editas Medicine (EDIT) to Underperform from Buy with a price target of $1, down from $13, after the company recently announced plans to out-license their reni-cel program, which ...